Active Stocks
Tue Mar 19 2024 12:20:41
  1. Tata Consultancy Services share price
  2. 4,019.20 -3.03%
  1. Tata Steel share price
  2. 148.80 -0.53%
  1. Bharti Airtel share price
  2. 1,234.95 0.81%
  1. Power Grid Corporation Of India share price
  2. 260.00 -1.89%
  1. ITC share price
  2. 410.00 -1.77%
Business News/ Companies / News/  Reckitt Benckiser CEO Rakesh Kapoor aims for comeback from worst year ever
BackBack

Reckitt Benckiser CEO Rakesh Kapoor aims for comeback from worst year ever

Reckitt Benckiser CEO Rakesh Kapoor has moved to separate its home-care and health businesses, sharpening his focus on brands such as Strepsils and Mucinex

Reckitt Benckiser CEO Rakesh Kapoor is optimistic about the pharmaceutical giant’s growth prospects. Photo: ReutersPremium
Reckitt Benckiser CEO Rakesh Kapoor is optimistic about the pharmaceutical giant’s growth prospects. Photo: Reuters

London: Reckitt Benckiser Group Plc says it’ll bounce back from its worst year ever.

The Slough, England-based maker of Durex condoms and Nurofen painkillers forecast that comparable sales will rise by 2% to 3% in 2018, after the first 12-month period of stagnant sales in the company’s history. On that basis, sales were up 2% in the fourth quarter.

The company is eyeing a comeback from a sour year marred by a cyberattack and lacklustre demand for new products. Chief executive officer Rakesh Kapoor has moved to separate its home-care and health businesses, sharpening his focus on brands such as Strepsils and Mucinex. Reckitt became a leader in infant nutrition with the acquisition of Mead Johnson Nutrition Co.

“We returned to growth after a solid finish to the year, our acquisition of MJN is firmly on track and the creation of two business units—RB Health and RB Hygiene Home—will drive long-term growth," Kapoor said Monday in a statement.

Reckitt Benckiser is one of two remaining bidders vying to acquire Pfizer’s consumer-health business, which includes brands such as Advil and ChapStick lip balm, according to people familiar with the matter. UK drugmaker GlaxoSmithKline Plc is the other.

A takeover, which could fetch as much as $20 billion, would be the company’s largest since the Mead Johnson deal was completed last year. Bloomberg

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 19 Feb 2018, 07:27 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App

Chat with MintGenie